NRNP 6552 WOMEN’S HEALTH MIDTERM
2025 | Original Graduate Nursing Practice Exam
100 Multiple-Choice Questions with Answers and Rationales
Independent practice material — not an actual Walden University course exam.
Questions are original and are not copied from a live exam, proprietary test bank, or university
assessment. This document is not Walden University-endorsed, professor-verified, or a
representation of the NRNP 6552 midterm blueprint. It is a study resource broadly organized
around the women’s health and primary-care topics listed in the request and advanced-practice
nursing concepts.
Educational use only. Clinical guidelines and laws may vary or change; confirm current local
guidance, prescribing information, scope-of-practice rules, and jurisdiction-specific consent and
reporting requirements before applying information in practice.
Reference basis includes the 2024 USPSTF breast-screening recommendation, CDC U.S.
Medical Eligibility Criteria for Contraceptive Use (2024), CDC STI treatment guidance, ACOG
patient and practice guidance, and other standard women’s health references.
Page 1 of 36
,Table of Contents
Section 1: Women’s Health History, Assessment & Health Promotion (Questions 1–15)
...................................... 3
Section 2: Reproductive Anatomy, Physiology & the Menstrual Cycle (Questions 16–30)
...................................... 8
Section 3: Contraception, Family Planning & Sexual Health Counseling (Questions 31–45)
...................................... 13
Section 4: Common Gynecologic Conditions & Infections (Questions 46–60) ......................................
18
Section 5: Breast Health, Screening & Disorders (Questions 61–75) ...................................... 23
Section 6: Perimenopause, Menopause & Hormone Therapy (Questions 76–90)
...................................... 28
Section 7: Psychosocial, Cultural & Ethical Issues in Women’s Health (Questions 91–100)
...................................... 33
Page 2 of 36
,Section 1: Women’s Health History, Assessment & Health Promotion
(Questions 1–15)
Q1: Which recommendation is appropriate for breast screening for average-risk patients?
A. Recommend annual mammography for every patient regardless of risk
B. Use screening MRI instead of mammography for all average-risk patients
C. Recommend biennial mammography through age 74, with individualized decisions if risk or
health status changes [CORRECT]
D. Wait until a palpable mass develops before imaging
Correct Answer: C
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk require a separate
diagnostic/risk-based plan. The other options are less appropriate, unsafe, or inconsistent with
the clinical priority.
Q2: Which clinical principle should guide care for breast screening for average-risk
patients?
A. Stop all screening at age 55
B. Recommend biennial mammography through age 74, with individualized decisions if risk or
health status changes [CORRECT]
C. Wait until a palpable mass develops before imaging
D. Use screening MRI instead of mammography for all average-risk patients
Correct Answer: B
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk require a separate
diagnostic/risk-based plan. The other options are less appropriate, unsafe, or inconsistent with
the clinical priority.
Q3: Situation: a healthy 58-year-old with no breast symptoms or high-risk history asks
how often to have screening mammography. For breast screening for average-risk
patients, which evidence-based principle applies?
A. Use screening MRI instead of mammography for all average-risk patients
B. Recommend biennial mammography through age 74, with individualized decisions if risk or
health status changes [CORRECT]
C. Stop all screening at age 55
D. Recommend annual mammography for every patient regardless of risk
Correct Answer: B
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk require a separate
diagnostic/risk-based plan. The other options are less appropriate, unsafe, or inconsistent with
the clinical priority.
Page 3 of 36
, Q4: A patient presents with the following history: a healthy 58-year-old with no breast
symptoms or high-risk history asks how often to have screening mammography. Which
action is most appropriate?
A. Recommend annual mammography for every patient regardless of risk
B. Recommend biennial mammography through age 74, with individualized decisions if risk or
health status changes [CORRECT]
C. Wait until a palpable mass develops before imaging
D. Stop all screening at age 55
Correct Answer: B
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk require a separate
diagnostic/risk-based plan. The other options are less appropriate, unsafe, or inconsistent with
the clinical priority.
Q5: Priority situation: a healthy 58-year-old with no breast symptoms or high-risk history
asks how often to have screening mammography. Which action addresses the
highest-risk issue?
A. Use screening MRI instead of mammography for all average-risk patients
B. Recommend biennial mammography through age 74, with individualized decisions if risk or
health status changes [CORRECT]
C. Recommend annual mammography for every patient regardless of risk
D. Wait until a palpable mass develops before imaging
Correct Answer: B
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk require a separate
diagnostic/risk-based plan. The other options are less appropriate, unsafe, or inconsistent with
the clinical priority.
Q6: Which recommendation is appropriate for cervical screening interval and risk status?
A. Stop screening because she received HPV vaccination
B. Explain that routine screening is not yet due under the 3-year cytology interval used for
average-risk ages 21–29 [CORRECT]
C. Order annual HPV cotesting for every patient younger than 30
D. Perform cervical screening at every preventive visit
Correct Answer: B
Rationale: For average-risk patients ages 21–29, the final USPSTF guidance in effect in 2025
recommends cytology every 3 years; vaccination does not remove the need for screening. The
other options are less appropriate, unsafe, or inconsistent with the clinical priority.
Page 4 of 36
2025 | Original Graduate Nursing Practice Exam
100 Multiple-Choice Questions with Answers and Rationales
Independent practice material — not an actual Walden University course exam.
Questions are original and are not copied from a live exam, proprietary test bank, or university
assessment. This document is not Walden University-endorsed, professor-verified, or a
representation of the NRNP 6552 midterm blueprint. It is a study resource broadly organized
around the women’s health and primary-care topics listed in the request and advanced-practice
nursing concepts.
Educational use only. Clinical guidelines and laws may vary or change; confirm current local
guidance, prescribing information, scope-of-practice rules, and jurisdiction-specific consent and
reporting requirements before applying information in practice.
Reference basis includes the 2024 USPSTF breast-screening recommendation, CDC U.S.
Medical Eligibility Criteria for Contraceptive Use (2024), CDC STI treatment guidance, ACOG
patient and practice guidance, and other standard women’s health references.
Page 1 of 36
,Table of Contents
Section 1: Women’s Health History, Assessment & Health Promotion (Questions 1–15)
...................................... 3
Section 2: Reproductive Anatomy, Physiology & the Menstrual Cycle (Questions 16–30)
...................................... 8
Section 3: Contraception, Family Planning & Sexual Health Counseling (Questions 31–45)
...................................... 13
Section 4: Common Gynecologic Conditions & Infections (Questions 46–60) ......................................
18
Section 5: Breast Health, Screening & Disorders (Questions 61–75) ...................................... 23
Section 6: Perimenopause, Menopause & Hormone Therapy (Questions 76–90)
...................................... 28
Section 7: Psychosocial, Cultural & Ethical Issues in Women’s Health (Questions 91–100)
...................................... 33
Page 2 of 36
,Section 1: Women’s Health History, Assessment & Health Promotion
(Questions 1–15)
Q1: Which recommendation is appropriate for breast screening for average-risk patients?
A. Recommend annual mammography for every patient regardless of risk
B. Use screening MRI instead of mammography for all average-risk patients
C. Recommend biennial mammography through age 74, with individualized decisions if risk or
health status changes [CORRECT]
D. Wait until a palpable mass develops before imaging
Correct Answer: C
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk require a separate
diagnostic/risk-based plan. The other options are less appropriate, unsafe, or inconsistent with
the clinical priority.
Q2: Which clinical principle should guide care for breast screening for average-risk
patients?
A. Stop all screening at age 55
B. Recommend biennial mammography through age 74, with individualized decisions if risk or
health status changes [CORRECT]
C. Wait until a palpable mass develops before imaging
D. Use screening MRI instead of mammography for all average-risk patients
Correct Answer: B
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk require a separate
diagnostic/risk-based plan. The other options are less appropriate, unsafe, or inconsistent with
the clinical priority.
Q3: Situation: a healthy 58-year-old with no breast symptoms or high-risk history asks
how often to have screening mammography. For breast screening for average-risk
patients, which evidence-based principle applies?
A. Use screening MRI instead of mammography for all average-risk patients
B. Recommend biennial mammography through age 74, with individualized decisions if risk or
health status changes [CORRECT]
C. Stop all screening at age 55
D. Recommend annual mammography for every patient regardless of risk
Correct Answer: B
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk require a separate
diagnostic/risk-based plan. The other options are less appropriate, unsafe, or inconsistent with
the clinical priority.
Page 3 of 36
, Q4: A patient presents with the following history: a healthy 58-year-old with no breast
symptoms or high-risk history asks how often to have screening mammography. Which
action is most appropriate?
A. Recommend annual mammography for every patient regardless of risk
B. Recommend biennial mammography through age 74, with individualized decisions if risk or
health status changes [CORRECT]
C. Wait until a palpable mass develops before imaging
D. Stop all screening at age 55
Correct Answer: B
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk require a separate
diagnostic/risk-based plan. The other options are less appropriate, unsafe, or inconsistent with
the clinical priority.
Q5: Priority situation: a healthy 58-year-old with no breast symptoms or high-risk history
asks how often to have screening mammography. Which action addresses the
highest-risk issue?
A. Use screening MRI instead of mammography for all average-risk patients
B. Recommend biennial mammography through age 74, with individualized decisions if risk or
health status changes [CORRECT]
C. Recommend annual mammography for every patient regardless of risk
D. Wait until a palpable mass develops before imaging
Correct Answer: B
Rationale: The 2024 USPSTF recommendation supports biennial mammography for
average-risk women ages 40–74; symptoms or elevated risk require a separate
diagnostic/risk-based plan. The other options are less appropriate, unsafe, or inconsistent with
the clinical priority.
Q6: Which recommendation is appropriate for cervical screening interval and risk status?
A. Stop screening because she received HPV vaccination
B. Explain that routine screening is not yet due under the 3-year cytology interval used for
average-risk ages 21–29 [CORRECT]
C. Order annual HPV cotesting for every patient younger than 30
D. Perform cervical screening at every preventive visit
Correct Answer: B
Rationale: For average-risk patients ages 21–29, the final USPSTF guidance in effect in 2025
recommends cytology every 3 years; vaccination does not remove the need for screening. The
other options are less appropriate, unsafe, or inconsistent with the clinical priority.
Page 4 of 36
